R Abalo1,2, C Chen3,4, G Vera1,2, J Fichna3,5, G A Thakur6, A E López-Pérez2,7, A Makriyannis8, M I Martín-Fontelles1,2, M Storr3. 1. Área de Farmacología y Nutrición y Unidad Asociada al Instituto de Química Médica (IQM) y al Centro de Investigación de Alimentos (CIAL) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain. 2. Grupo de Excelencia Investigadora URJC-Banco de Santander-Grupo multidisciplinar de investigación y tratamiento del dolor (i+DOL), Alcorcón, Madrid, Spain. 3. MedizinischeKlinik 2 der Ludwig-Maximilians Universität München, Munich, Germany. 4. Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China. 5. Department of Biochemistry, Medical University of Lodz, Lodz, Poland. 6. Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA. 7. Unidad del Dolor, Servicio de Anestesiología, Hospital General Universitario Gregorio Marañón (HGUGM), Madrid, Spain. 8. Center for Drug Discovery, Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern Universtiy, Boston, MA, USA.
Abstract
BACKGROUND: Cannabinoids have been traditionally used for the treatment of gastrointestinal (GI) symptoms, but the associated central effects, through cannabinoid-1 receptors (CB1R), constitute an important drawback. Our aims were to characterize the effects of the recently developed highly potent long-acting megagonist AM841 on GI motor function and to determine its central effects in rats. METHODS: Male Wistar rats were used for in vitro and in vivo studies. The effect of AM841 was tested on electrically induced twitch contractions of GI preparations (in vitro) and on GI motility measured radiographically after contrast administration (in vivo). Central effects of AM841 were evaluated using the cannabinoid tetrad. The non-selective cannabinoid agonist WIN 55,212-2 (WIN) was used for comparison. The CB1R (AM251) and CB2R (AM630) antagonists were used to characterize cannabinoid receptor-mediated effects of AM841. KEY RESULTS: AM841 dose-dependently reduced in vitro contractile activity of rat GI preparations via CB1R, but not CB2R or opioid receptors. In vivo, AM841 acutely and potently reduced gastric emptying and intestinal transit in a dose-dependent and AM251-sensitive manner. The in vivo GI effects of AM841 at 0.1 mg/kg were comparable to those induced by WIN at 5 mg/kg. However, at this dose, AM841 did not induce any sign of the cannabinoid tetrad, whereas WIN induced significant central effects. CONCLUSIONS & INFERENCES: The CB1R megagonist AM841 may potently depress GI motor function in the absence of central effects. This effect may be mediated peripherally and may be useful in the treatment of GI motility disorders.
BACKGROUND:Cannabinoids have been traditionally used for the treatment of gastrointestinal (GI) symptoms, but the associated central effects, through cannabinoid-1 receptors (CB1R), constitute an important drawback. Our aims were to characterize the effects of the recently developed highly potent long-acting megagonist AM841 on GI motor function and to determine its central effects in rats. METHODS: Male Wistar rats were used for in vitro and in vivo studies. The effect of AM841 was tested on electrically induced twitch contractions of GI preparations (in vitro) and on GI motility measured radiographically after contrast administration (in vivo). Central effects of AM841 were evaluated using the cannabinoid tetrad. The non-selective cannabinoid agonist WIN 55,212-2 (WIN) was used for comparison. The CB1R (AM251) and CB2R (AM630) antagonists were used to characterize cannabinoid receptor-mediated effects of AM841. KEY RESULTS:AM841 dose-dependently reduced in vitro contractile activity of rat GI preparations via CB1R, but not CB2R or opioid receptors. In vivo, AM841 acutely and potently reduced gastric emptying and intestinal transit in a dose-dependent and AM251-sensitive manner. The in vivo GI effects of AM841 at 0.1 mg/kg were comparable to those induced by WIN at 5 mg/kg. However, at this dose, AM841 did not induce any sign of the cannabinoid tetrad, whereas WIN induced significant central effects. CONCLUSIONS & INFERENCES: The CB1R megagonist AM841 may potently depress GI motor function in the absence of central effects. This effect may be mediated peripherally and may be useful in the treatment of GI motility disorders.
Authors: Robert P Picone; Atmaram D Khanolkar; Wei Xu; Lionel A Ayotte; Ganesh A Thakur; Dow P Hurst; Mary E Abood; Patricia H Reggio; Donna J Fournier; Alexandros Makriyannis Journal: Mol Pharmacol Date: 2005-09-12 Impact factor: 4.436
Authors: Edward S Kimball; Craig R Schneider; Nathaniel H Wallace; Pamela J Hornby Journal: Am J Physiol Gastrointest Liver Physiol Date: 2006-03-30 Impact factor: 4.052
Authors: D R Compton; K C Rice; B R De Costa; R K Razdan; L S Melvin; M R Johnson; B R Martin Journal: J Pharmacol Exp Ther Date: 1993-04 Impact factor: 4.030
Authors: Claudia R Vianna; Jose Donato; Jari Rossi; Michael Scott; Kyriakos Economides; Lauren Gautron; Stephanie Pierpont; Carol F Elias; Joel K Elmquist Journal: J Neurosci Date: 2012-07-25 Impact factor: 6.167
Authors: Andrei Sibaev; Birol Yüce; Markus Kemmer; Luc Van Nassauw; Ulli Broedl; Hans D Allescher; Burkhard Göke; Jean-Pierre Timmermans; Martin Storr Journal: Am J Physiol Gastrointest Liver Physiol Date: 2008-11-25 Impact factor: 4.052
Authors: Gema Vera; Ana E López-Pérez; José A Uranga; Rocío Girón; Ma Isabel Martín-Fontelles; Raquel Abalo Journal: Front Pharmacol Date: 2017-02-06 Impact factor: 5.810